UPS’s pessimistic outlook fell 6.99%
American express giant UPS (UPS-US)’s second-quarter revenue and profit exceeded Wall Street analysts’ expectations, but the market is concerned that the e-commerce boom driven by the epidemic is gradually fading. On Wednesday (27th) the stock price fell 6.99% to 195.19 per share. Dollar.
UPS’s second-quarter revenue increased by 14.5% to 23.42 billion US dollars, better than Refinitiv analysts’ expectations of 23.24 billion US dollars, adjusted profit per share of 3.06 US dollars, and also better than Refinitiv analysts estimated 2.82 US dollars.
The company said that the domestic business volume fell by 2.9% in the second quarter, mainly due to a 4% decrease in e-commerce business compared with the same period last year. Cowen Research analyst Cowen Research wrote in a report: “Investors may interpret this as an epidemic-driven demand is slowing.”
In addition, UPS also stated that the volume of domestic parcels may be under pressure in the second half of this year, because some consumers return to shop for shopping, and when the goods are affected by ports and railways, customers are scrambling to replenish inventory.
Modena vaccine production package fell 2.19%
Moderna (MRNA-US) has delayed the production of vaccines from partners outside the United States due to laboratory testing issues and slowed the company’s vaccine launches in other markets. Its stock price fell 2.19% on Wednesday to US$328.50 per share.
A Modena spokesperson said that there is currently no safe inventory for the faster delivery of vaccines, which means that no inventory can alleviate this delay. However, the company spokesperson also said that the current problem has been resolved, but the delivery time of vaccines in the next 2 to 4 weeks is likely to undergo a short-term adjustment.
Modena production problems delayed delivery, which may affect South Korea’s vaccination plan. Jung Eun-young, head of the South Korean vaccine procurement team, said that the supply problem is related to the Lonza Group in Switzerland, which is responsible for production, and Laboratorios Farmaceuticos Rovi SA, which is responsible for filling vaccines in Spain.
F5 Networks’ third-quarter financial report blessed, soaring 6.20%
F5 Networks (FFIV-US), a network service company, was backed by its brilliant financial report recently. Its stock price rose 6.20% to US$204.57 per share on Tuesday.
F5 Networks reported revenue of US$652 million in the third quarter of the fiscal year and earnings per share of US$2.76, both better than the US$638 million and US$2.46 estimated by Refinitiv analysts.
In addition, F5 Networks also announced optimistic financial forecasts for the fourth quarter. Revenue is expected to be between US$660 million and US$680 million, and profit per share will be between US$2.68 and US$2.80. The Zacks survey consensus is 6.632. Billion US dollars and 2.73 US dollars. The company said that the surge in demand for cloud services is the main growth driver for this quarter’s earnings.